FTN Equity Starts Mylan Labs (MYL) at Neutral
MYL Hot Sheet
Rating Summary:6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 1
FTN Equity initiates coverage on Mylan Labs (NYSE: MYL) with a Neutral rating.
For more analyst ratings on MYL click here.
Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients (APIs).
For more analyst ratings on MYL click here.
Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic, brand, and branded generic pharmaceutical products and active pharmaceutical ingredients (APIs).
You May Also Be Interested In
- Mylan (MYL) Launches Generic Bonviva Tabs (RHHBY) in Italy & the U.K.
- Nomura Securities Maintains a 'Buy' on Melco Crown Entertainment (MPEL); Raising PT and Estimates
- Bernstein Starts Onyx Pharmaceuticals (ONXX) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
